The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs

The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs

<strong>Background:</strong> Extended-release niacin with laropiprant did not significantly reduce the risk of major vascular events and increased the risk of serious adverse events in HPS2-THRIVE but its net effects on health and healthcare costs are unknown. <strong>Methods an...

Bibliografske podrobnosti
Main Authors:	Kent, S, Haynes, R, Hopewell, J, Parish, S, Gray, A, Landray, M, Collins, R, Armitage, J, Mihaylova, B
Format:	Journal article
Izdano:	American Heart Association 2016

Podobne knjige/članki

Effects of extended-release niacin with laropiprant in high-risk patients.
od: Landray, M, et al.
Izdano: (2014)

Serious adverse effects of extended-release niacin/laropiprant: results from the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial
od: Haynes, R, et al.
Izdano: (2019)

The safety, tolerability and biochemical efficacy of extended release niacin and laropiprant in a major randomised clinical trial
od: Haynes, R
Izdano: (2013)

Effects of extended release niacin/laropiprant in 25,673 high-risk individuals receiving statin-based therapy: the HPS2-THRIVE randomized placebo-controlled trial
od: Landray, M, et al.
Izdano: (2014)

Niacin for reduction of cardiovascular risk.
od: Landray, M, et al.
Izdano: (2014)

Niacin for reduction of cardiovascular risk.
od: Landray, M, et al.
Izdano: (2014)

Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality
od: Parish, S, et al.
Izdano: (2010)

Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
od: Emberson, JR, et al.
Izdano: (2010)

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
od: HPS2-THRIVE Collaborative Group, et al.
Izdano: (2013)

Effects of niacin on atherosclerosis and vascular function.
od: Ruparelia, N, et al.
Izdano: (2011)

Associations of toothbrushing behaviour with risks of vascular and nonvascular diseases in Chinese adults
od: Zhuang, Z, et al.
Izdano: (2021)

Niacin: old habits die hard
od: Haynes, R, et al.
Izdano: (2016)

Association of CETP gene variants with risk for vascular and nonvascular diseases among Chinese adults
od: Millwood, I, et al.
Izdano: (2017)

Lipoprotein-associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality.
od: Heart Protection Study Collaborative Group
Izdano: (2010)

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
od: Mihaylova, B, et al.
Izdano: (2005)

Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
od: Mihaylova, B, et al.
Izdano: (2009)

Economic analysis of simvastatin in 20,536 people at different levels of vascular disease risk based on US costs: Randomised placebo-controlled trial
od: Mihaylova, B, et al.
Izdano: (2005)

Niacin skin test response in dyslexia.
od: Cyhlarova, E, et al.
Izdano: (2007)

Niacin skin test response in dyslexia
od: Cyhlarova, E, et al.
Izdano: (2007)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
od: Hopewell, J, et al.
Izdano: (2009)

NAD deficiency, congenital malformations and niacin supplementation
od: Shi, H, et al.
Izdano: (2017)

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.
od: Erqou, S, et al.
Izdano: (2009)

Bowel movement frequency and risks of major vascular and nonvascular diseases: a population-based cohort study among Chinese adults
od: Yang, L, et al.
Izdano: (2020)

Niacin in cardiovascular disease: Recent preclinical and clinical developments
od: Digby, J, et al.
Izdano: (2012)

Niacin in cardiovascular disease: recent preclinical and clinical developments.
od: Digby, J, et al.
Izdano: (2012)

Metformin immediate and extended-release adverse events and effects on metabolic parameters: a meta-analysis
od: Alshadfan, Hisham, et al.
Izdano: (2023)

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.
od: Hopewell, J, et al.
Izdano: (2011)

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.
od: Parish, S, et al.
Izdano: (2012)

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
od: Mihaylova, B, et al.
Izdano: (2006)

Hospital costs associated with adverse events in people with diabetes in the UK
od: Keng, MJ, et al.
Izdano: (2022)

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
od: Hopewell, J, et al.
Izdano: (2011)

Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis.
od: Danesh, J, et al.
Izdano: (2005)

Body mass index and healthcare costs: a systematic literature review of individual participant data studies
od: Kent, S, et al.
Izdano: (2017)

Decrements in health‐related quality of life associated with adverse events in people with diabetes
od: Keng, MJ, et al.
Izdano: (2021)

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
od: Hopewell, J, et al.
Izdano: (2011)

Polymers for extended-release administration
od: Paolini, Marion, et al.
Izdano: (2020)

Aspirin for primary prevention of vascular disease in people with diabetes.
od: Haynes, R, et al.
Izdano: (2009)

Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.
od: Armitage, J, et al.
Izdano: (2009)

The investigation and analysis of critical incidents and adverse events in healthcare.
od: Woloshynowych, M, et al.
Izdano: (2005)

The investigation and analysis of critical incidents and adverse events in healthcare.
od: Woloshynowych, M, et al.
Izdano: (2005)